Article
Benzimidazole-containing HCV NS5A inhibitors: effect of 4-substituted pyrrolidines in balancing genotype 1a and 1b potency.
Bioorganic & medicinal chemistry letters - 15 Feb 2015
Henderson James A, Bilimoria Darius, Bubenik Monica, Cadilhac Caroline, Cottrell Kevin M, Dietrich Evelyne, Denis Francois, Ewing Nigel, Falardeau Guy, Giroux Simon, Grey Ronald, L'Heureux Lucille, Liu Bingcan, Mani Nagraj, Morris Mark, Nicolas Olivier, Pereira Oswy Z, Poisson Carl, Govinda Rao B, Reddy T Jagadeeswar, Selliah Subajini, Shawgo Rebecca S, Vaillancourt Louis, Wang Jian, Yannopoulos Constantin G, Chauret Nathalie, Berlioz-Seux Francoise, Chan Laval C, Das Sanjoy K, Grillot Anne-Laure, Bennani Youssef L, Maxwell John P
Abstract excerpt
The treatment of HCV with highly efficacious, well-tolerated, interferon-free regimens is a compelling clinical goal. Trials employing combinations of direct-acting antivirals that include NS5A inhibitors have shown significant promise in meeting this challenge. Herein, we describe our efforts to identify inhibitors of NS5A and report on the discovery of benzimidazole-containing analogs with subnanomolar potency...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.